Boswellia: Research
Overview
This page provides a curated overview of selected peer-reviewed papers examining Boswellia, a resin-derived botanical most commonly studied as extracts of Boswellia serrata. The summaries describe published findings and are presented for educational purposes as part of a clinician-led review of the scientific literature.
Important Context for Readers
Scientific studies examine outcomes in defined populations under specific research conditions. Results reported in individual studies may not apply to all individuals, and findings should not be interpreted as guaranteed outcomes. This page summarizes selected research examining outcomes and biological mechanisms studied in relation to boswellia. It is not intended to provide medical advice, diagnosis, or treatment recommendations. This page is provided for educational purposes and does not include product recommendations or affiliate links.
Summary of Evidence
The strongest clinical evidence concerns knee discomfort, stiffness, and physical function in adults with knee osteoarthritis. Several small randomized trials reported favorable findings. Systematic reviews have reached differing conclusions, reflecting variation in formulations, comparators, study quality, and outcome reporting.
The evidence remains limited by small samples, relatively short follow-up, and frequent manufacturer involvement. Early improvements in selected outcomes do not establish reliable immediate relief or justify as-needed dosing. Preliminary imaging findings do not establish cartilage regeneration or prevention of structural progression.
Key Areas of Research
Mechanisms, Absorption, and Clinical Context
Evidence strength: Low for proposed mechanisms; limited human pharmacokinetic evidence.
These papers provide essential context for interpreting proposed mechanisms, extract differences, and the effect of food on absorption. They are not substitutes for clinical-outcome trials.
1) Abdel-Tawab M, Werz O, Schubert-Zsilavecz M. Boswellia serrata: an overall assessment of in vitro, preclinical, pharmacokinetic and clinical data. Clin Pharmacokinet. 2011.
PMID: 21553931
DOI: https://doi.org/10.2165/11586800-000000000-00000
Population: Published laboratory, human pharmacokinetic, and clinical studies of Boswellia extracts and boswellic acids.
Design: Critical narrative review of mechanisms, pharmacokinetics, and clinical findings.
Key findings:
Low circulating KBA and AKBA concentrations raise questions about how much direct 5-lipoxygenase inhibition contributes to effects in humans.
Other constituents and molecular targets may be relevant; laboratory activity alone does not establish clinical benefit.
The review also provides historical context for the limited clinical research in digestive and respiratory conditions.
2) Sterk V, Büchele B, Simmet T. Effect of food intake on the bioavailability of boswellic acids from a herbal preparation in healthy volunteers. Planta Med. 2004.
PMID: 15643550
DOI: https://doi.org/10.1055/s-2004-835844
Population: Healthy male volunteers.
Design: Randomized, open-label, single-dose crossover study comparing 786 mg of a conventional Boswellia dry extract in the fasted state and with a standardized high-fat meal.
Key findings:
Food substantially increased systemic exposure to several boswellic acids.
The study supports a food effect for the tested conventional extract, not a demonstrated increase in clinical benefit or an identical food requirement for every formulation
Knee Comfort and Physical Function
Evidence strength: Low to Moderate; conclusions vary across analyses.
These reviews synthesize the human evidence and provide the principal context for efficacy, uncertainty, and short-term tolerability. Their included trials overlap and should not be counted as separate bodies of participants. These trials support interpretation of conventional extracts, 5-LOXIN®, Aflapin®/AprèsFlex®, and Boswellin® preparations. Daily totals are distinguished from the actual dosing schedule used in each study.
3) Bannuru RR, Osani MC, Al-Eid F, et al. Efficacy of curcumin and Boswellia for knee osteoarthritis: Systematic review and meta-analysis. Semin Arthritis Rheum. 2018.
PMID: 29622343
DOI: https://doi.org/10.1016/j.semarthrit.2018.03.001
Population: Adults with knee osteoarthritis across 11 randomized trials (n=1,009 across both curcuminoid and Boswellia studies, not Boswellia alone).
Design: Systematic review and meta-analysis evaluating curcuminoid or Boswellia formulations against placebo or NSAIDs.
Key findings:
In placebo-controlled comparisons, Boswellia formulations improved pain and physical function, without significant differences in reported safety outcomes.
Overall study quality was low, and the authors considered the evidence inadequate for firm clinical-practice recommendations.
The review's comparisons with approved NSAIDs concerned curcuminoids, not evidence that Boswellia is equivalent to NSAIDs.
4) Yu G, Xiang W, Zhang T, et al. Effectiveness of Boswellia and Boswellia extract for osteoarthritis patients: a systematic review and meta-analysis. BMC Complement Med Ther. 2020.
PMID: 32680575
DOI: https://doi.org/10.1186/s12906-020-02985-6
Population: Adults with osteoarthritis across seven randomized trials (n=545).
Design: Systematic review and meta-analysis comparing Boswellia-containing interventions with placebo or active controls.
Key findings:
Pooled results favored Boswellia for visual-analog pain, WOMAC pain, stiffness, function, and Lequesne scores.
The authors suggested at least four weeks of use before judging response.
Differences in formulations, outcome scales, and small study samples limit use of a single pooled estimate as an expected individual benefit.
5) Dalmonte T, Andreani G, Rudelli C, et al. Efficacy of Extracts of Oleogum Resin of Boswellia in the Treatment of Knee Osteoarthritis: A Systematic Review and Meta-Analysis. Phytother Res. 2024.
PMID: 39314013
DOI: https://doi.org/10.1002/ptr.8336
Population: Adults with knee osteoarthritis across 13 randomized controlled studies.
Design: Systematic review and meta-analysis, including subgroup analyses by comparator.
Key findings:
Overall pooled WOMAC and visual-analog pain effects were not statistically significant, with substantial heterogeneity.
Placebo-controlled subgroup findings were more favorable for WOMAC outcomes.
This newer review is retained because it directly supports the monograph's discussion of conflicting pooled evidence.
6) Kimmatkar N, Thawani V, Hingorani L, et al. Efficacy and tolerability of Boswellia serrata extract in treatment of osteoarthritis of knee—a randomized double blind placebo controlled trial. Phytomedicine. 2003.
PMID: 12622457
DOI: https://doi.org/10.1078/094471103321648593
Population: Adults with knee osteoarthritis (n=30).
Design: Randomized, double-blind, placebo-controlled crossover trial with eight-week intervention periods.
Key findings:
Knee pain, knee flexion, and walking distance improved during Boswellia treatment compared with placebo.
No radiographic improvement was observed; minor gastrointestinal adverse effects occurred.
This widely cited early trial supports conventional-extract research but is too small to establish broad product equivalence.
7) Sengupta K, Alluri KV, Satish AR, et al. A double blind, randomized, placebo controlled study of the efficacy and safety of 5-Loxin for treatment of osteoarthritis of the knee. Arthritis Res Ther. 2008.
PMID: 18667054
DOI: https://doi.org/10.1186/ar2461
Population: Adults with knee osteoarthritis (n=75 randomized; 70 completed).
Design: Ninety-day randomized, double-blind, placebo-controlled trial of 5-LOXIN® 50 mg twice daily or 125 mg twice daily—total daily doses of 100 or 250 mg.
Key findings:
Both doses improved pain measures; the 250 mg daily group showed more consistent benefits across pain, stiffness, and function outcomes.
Some benefits were detected by day 7, particularly with 250 mg daily; not every endpoint was significantly better than placebo at the lower dose.
Short-term laboratory safety findings were reassuring, but the small, manufacturer-supported trial cannot establish uncommon or long-term risks.
8) Sengupta K, Krishnaraju AV, Vishal AA, et al. Comparative Efficacy and Tolerability of 5-Loxin® and Aflapin® Against Osteoarthritis of the Knee: A Double Blind, Randomized, Placebo Controlled Clinical Study. Int J Med Sci. 2010.
PMID: 21060724
DOI: https://doi.org/10.7150/ijms.7.366
Population: Adults with knee osteoarthritis (n=60 randomized; 57 completed).
Design: Ninety-day randomized, double-blind trial of Aflapin® 50 mg twice daily, 5-LOXIN® 50 mg twice daily, or placebo; both active arms provided 100 mg daily.
Key findings:
Both active arms reported improvements in pain and function; Aflapin showed more favorable results on several measures.
Selected Aflapin outcomes improved by day 7.
Only 20 participants were randomized per arm, so this comparison does not establish definitive superiority of one extract.
9) Vishal AA, Mishra A, Raychaudhuri SP. A Double Blind, Randomized, Placebo Controlled Clinical Study Evaluates the Early Efficacy of Aflapin® in Subjects with Osteoarthritis of Knee. Int J Med Sci. 2011.
PMID: 22022214
DOI: https://doi.org/10.7150/ijms.8.615
Population: Adults with knee osteoarthritis (n=60 randomized; 59 completed).
Design: Thirty-day randomized, double-blind, placebo-controlled trial of Aflapin® 50 mg twice daily, totaling 100 mg daily.
Key findings:
Pain and function outcomes favored Aflapin at day 30.
Visual-analog pain and Lequesne scores favored Aflapin by day 5; WOMAC differences were not significant at that early time point.
This small, manufacturer-funded trial supports cautious, outcome-specific early-onset wording.
10) Majeed M, Majeed S, Narayanan NK, et al. A pilot, randomized, double-blind, placebo-controlled trial to assess the safety and efficacy of a novel Boswellia serrata extract in the management of osteoarthritis of the knee. Phytother Res. 2019.
PMID: 30838706
DOI: https://doi.org/10.1002/ptr.6338
Population: Adults with knee osteoarthritis (n=48 randomized; 42 completed).
Design: Pilot randomized, double-blind, placebo-controlled trial of Boswellin® extract 169.33 mg twice daily for 120 days.
Key findings:
The active group reported improved pain, stiffness, and physical function compared with placebo.
No serious adverse events were reported; imaging findings were exploratory and do not establish cartilage regeneration.
This manufacturer-affiliated trial directly supports the monograph's approximately 169 mg twice-daily research dose.
11) Majeed A, Majeed S, Satish G, et al. A standardized Boswellia serrata extract shows improvements in knee osteoarthritis within five days-a double-blind, randomized, three-arm, parallel-group, multi-center, placebo-controlled trial. Front Pharmacol. 2024.
PMID: 39092235
DOI: https://doi.org/10.3389/fphar.2024.1428440
Population: Adults with knee osteoarthritis (n=105 randomized; 98 completed).
Design: Ninety-day randomized, double-blind, placebo-controlled trial of Boswellin® Super 150 or 300 mg twice daily, totaling 300 or 600 mg daily.
Key findings:
Both doses improved pain and functional outcomes compared with placebo; early pain changes were reported by day 5.
No serious adverse events were reported, but larger and more diverse trials are needed.
12) Kumar B, Ghaytidak AB, Pandey AK, et al. A Standardized Boswellia serrata Extract Improves Knee Joint Function and Cartilage Morphology in Human Volunteers with Mild to Moderate Osteoarthritis in a Randomized Placebo-Controlled Study. J Am Nutr Assoc. 2025.
PMID: 39700461
DOI: https://doi.org/10.1080/27697061.2024.2438894
Population: Adults with Kellgren-Lawrence grade II–III knee osteoarthritis (n=80).
Design: Randomized, placebo-controlled 180-day trial of Aflapin® (SN13108F) 100 mg daily.
Key findings:
Pain, physical-function, walking, and stair-climb outcomes favored Aflapin.
MRI differences in cartilage measurements were reported, but independent replication is needed before interpreting them as disease modification.
Other Support
Evidence strength: Low.
13) Majumdar A, Prasad MAVV, Gandavarapu SR, et al. Efficacy and safety evaluation of Boswellia serrata and Curcuma longa extract combination in the management of chronic lower back pain: A randomised, double-blind, placebo-controlled clinical study. Explore (NY). 2025.
PMID: 39700654
DOI: https://doi.org/10.1016/j.explore.2024.103099
Population: Adults with chronic lower back pain (n=90).
Design: Randomized, double-blind, placebo-controlled trial evaluating CL20192, a combination of Boswellia serrata and Curcuma longa extracts, at 300 mg once daily for 90 days.
Key findings:
The combination group showed greater improvements in pain and disability scores than placebo.
Improvements in selected quality-of-life measures were reported.
Because the formulation contained both botanicals, the findings cannot establish the independent contribution of Boswellia.
14) Henrotin Y, Dierckxsens Y, Delisse G, et al. Curcuminoids and Boswellia serrata extracts combination decreases tendinopathy symptoms: findings from an open-label post-observational study. Curr Med Res Opin. 2021.
PMID: 33287570
DOI: https://doi.org/10.1080/03007995.2020.1860923
Population: Patients with tendinopathy at different anatomical sites (n=670).
Design: One-month, open-label, uncontrolled observational study evaluating a combination of Curcuma longa and Boswellia serrata extracts alongside standard care.
Key findings:
Pain and functional-limitation scores decreased during follow-up.
No severe product-related adverse effects were reported.
The uncontrolled design, concurrent care, and combination formulation prevent attribution of improvements specifically to Boswellia.
Safety and Tolerability
Evidence strength: Low.
15) Siemoneit U, Tausch L, Poeckel D, et al. Defined Structure-Activity Relationships of Boswellic Acids Determine Modulation of Ca2+ Mobilization and Aggregation of Human Platelets by Boswellia serrata Extracts. Planta Med. 2017.
PMID: 28403501
DOI: https://doi.org/10.1055/s-0043-107884
Population: Isolated human platelets studied under laboratory conditions.
Design: In vitro study examining how individual boswellic acids and Boswellia serrata extracts affected calcium mobilization and platelet aggregation.
Key findings:
AKBA inhibited platelet responses induced by collagen and a thromboxane-receptor agonist.
Other boswellic acids stimulated platelet activation, demonstrating effects that varied with chemical structure and extract composition.
These findings support possible effects on platelet function but do not establish increased bleeding risk or clinically significant medication interactions at usual supplemental doses.
16) Krüger P, Kanzer J, Hummel J, et al. Permeation of Boswellia extract in the Caco-2 model and possible interactions of its constituents KBA and AKBA with OATP1B3 and MRP2. Eur J Pharm Sci. 2009.
PMID: 19010411
DOI: https://doi.org/10.1016/j.ejps.2008.10.005
Population: Human Caco-2 intestinal cell cultures and experimental transporter-assay systems.
Design: In vitro permeability and transporter studies evaluating the boswellic acids KBA and AKBA.
Key findings:
KBA and AKBA modulated OATP1B3 and MRP2 transporter activity in laboratory assays.
Neither compound was identified as a P-glycoprotein substrate.
The findings identify potential interaction mechanisms but do not demonstrate clinically important changes in medication exposure in people taking oral Boswellia.
Educational Notice
These summaries are provided for educational purposes to review published scientific literature and should not be interpreted as medical advice, diagnosis, or treatment recommendations. Readers should consult qualified healthcare professionals for personal medical decisions.
FDA Disclaimer
These statements have not been evaluated by the U.S. Food and Drug Administration. Dietary supplements are not intended to diagnose, treat, cure, or prevent any disease.
FTC Affiliate Disclosure
Some pages on this website may contain affiliate links to products. If readers choose to purchase through those links, the site may receive a commission. Affiliate relationships do not influence the selection or discussion of scientific studies summarized on this reference page.